Special considerations in breast cancer risk and survival

Journal of Surgical Oncology

Volumn 71, Issue 4, 1999, Pages 250-260

  Newman, Lisa A ^a   Kuerer, Henry M ^b   Harper, Theresa ^a   Hunt, Kelly K ^a   Laronga, Christine ^a   Breslin, Tara ^a   Singletary, S Eva ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Estrogen; Hormone replacement therapy; Timing of breast cancer surgery

Indexed keywords

ANABOLIC AGENT; BELLERGAL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLONIDINE; DROLOXIFENE; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; IDOXIFENE; METHYLDOPA; ORAL CONTRACEPTIVE AGENT; PHYTOESTROGEN; PROGESTERONE; RALOXIFENE; TAMOXIFEN; VITAMIN D;

BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DIETARY INTAKE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MENSTRUAL CYCLE; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; DIETARY FATS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIFE STYLE; MENSTRUAL CYCLE; NUTRITIONAL SUPPORT; POSTMENOPAUSE; RISK; SURVIVAL RATE; TIME FACTORS;

EID: 0032765666     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199908)71:4<250::AID-JSO11>3.0.CO;2-3     Document Type: Review

References (126)

1. Kosary CL, Ries LAG, Miller BA, et al.: SEER Cancer Statistics Review, 1973-1992:Tables and Graphs. Bethesda, MD: National Cancer Institute. NIH Publication No. 95-2789. 1995.
2. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1986;2:104-107.
3. Kelsey JL, Gammon MD: The epidemiology of breast cancer. CA-A Cancer J Clinicians 1991:41:147-165.
4. Hulka BS, Liu ET, Lininger RA: Steroid hormones and risk of breast cancer. Cancer 1994;74:1111-1124.
5. Russo J, Tay LK, Russo IH: Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982:2:5-73.
6. Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer: The Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-253.
7. Pike MC, Spicer DV, Dahmoush L, et al.: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
8. Spicer DV, Pike MC: Breast cancer prevention through modulation of endogenous hormones. Breast Cancer Res Treat 1993; 28:179-193.
9. Dickson RB, Thompson EW, Lippman ME: Regulation of proliferation, invasion, and growth factor synthesis in breast cancer by steroids. J Steroid Biochem Mol Biol. 1990;37:305-316.
10. Cauley JA, Gutal JP, Kuller LH, et al.: The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989:129:1120-1131.
11. Moore M: Male breast cancer. In Harris JR, Lippman ME, Morrow M, Hellman S (eds): "Diseases of the Breast." Philadelphia, PA: Lippincott-Raven, 1996:859.
12. Dorgan JF, Longcope C, Stephenson HE, et al.: Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-539.
13. Toniolo PG, Levitz M, Zeleniuch-Jacquette A, et al.: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. JNCI 1995;87:190-197.
14. Berrino F, Muti P, Micleli A, et al.: Serum sex hormones levels after menopause and subsequent breast cancer. JNCI 1996;88: 291-296.
15. Bernstein L, Yuan JM, Ross RK, et al.: Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control 1990;1:51-58.
16. Hankinson SE, Willett WC, Manson JE, et al.: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-1299.
17. Khan SA, Rogers MAM, Khurana K, et al.: Estrogen receptor expression in breast epithelium and breast cancer risk. JNCI 1998;90:37-42.
18. Ricketts D, Turnbull L, Ryall G, et al.: Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991;51: 1817-1822.
19. Committee on the relationship between oral contraceptives and breast cancer. Institute of Medicine, Division of Health Promotion and Disease Prevention. Oral Contraceptives and Breast Cancer. Washington, DC:National Academy Press; 1991 (ISBN: 0-309-04493-6).
20. Pike MC, Henderson BE, Krailo MD, et al: Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983;926-929.
21. The Centers for Disease Control Cancer and Steroid Hormone Study. Long-term oral contraceptive use and the risk of breast cancer. JAMA 1983;249:1591-1595.
22. Stadel BV, Rubin GL, Webster LA, et al.: Oral contraceptives and breast cancer in young women. Lancet 1985:970-973.
23. Miller DR, Rosenberg L, Kaufman DW, et al.: Breast cancer risk in relation to early contraceptive use. Obstet Gynecol 1986;68: 863-868.
24. Jick SS, Walker AM, Stergachis A, et al.: Oral contraceptives and breast cancer. Br J Cancer 1989;59:618-621.
25. Romieu I, Willett WC, Colditz GA, et al.: Prospective study of oral contraceptive use and risk of breast cancer in women. JNCI 1989;81:1313-1321.
26. Weinstein AL, Mahoney MC, Nasca PC, et al.: Breast cancer risk and oral contraceptive use: Results from a large case-control study. Epidemiology 1991;2:353-358.
27. Wingo PA, Lee NC, Ory HW, et al.: Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 1991;78:161-170.
28. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives. Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-1727.
29. Smith HO, Kammerer-Doak DN, Barbo DM, et al.: Hormone replacement therapy in the menopause: A pro opinion. CA-A Cancer J Clinicians 1996;46:343-363.
30. Consensus Conference: Osteoporosis. JAMA 1984;252:799-802.
31. Bhatia NN, Bergman A, Karram MM: Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 1989;160:176-181.
32. Campbell S, Whitehead M: Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1977;4:31-47.
33. Sherwin BB: Estrogen and cognitive function in women. Proc Soc Exp Biol Med 1998;217:17-22.
34. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women; The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199-208.
35. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
36. Wenger NK, Speroff L, Packard B: Cardiovascular health and disease in women. NEJM 1993;329:247-256.
37. Grady D, Rubin SM, Petitti DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992;117:1016-1037.
38. Lindsay R: Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol 1987;156:1347-1351.
39. Weiss NS, Ufe CL, Ballard JH, et al.: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. NEJM 1980;303:1195-98.
40. Mack TM, Pike MC, Henderson BE, et al.: Estrogens and endometrial cancer in a retirement community. NEJM 1976;294: 1262-1261.
41. Boring JE, Bain CJ, Ehrmann RL: Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 1986;124:434-441.
42. Antunes CM, Stolley PD, Rosenshein NB, et al.: Endometrial cancer and estrogen use: Report of a large case-control study. NEJM 1979;300:9-13.
43. Hoover R, Gray LA, Cole P, et al.: Menopausal estrogens and breast cancer. NEJM 1976;295:401-405.
44. Gambrell RD, Maier RC, Sanders BI: Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-443.
45. Hunt K, Vessey M, McPherson K, et al.: Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-635.
46. Bergkvist L, Adami H-O, Persson I, et al.: The risk of breast cancer after estrogen and estrogen-progestin replacement. NEJM 1989;321:293-297.
47. Mills PK, Beeson L, Phillips RL, et al.: Prospective study of exogenous hormone use and breast cancer in Seventh-Day Adventists. Cancer 1989;64:591-597.
48. Colditz GA, Hankinson SE, Hunter DJ, et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. NEJM 1995;332:1589-1593.
49. Grodstein F, Stampfer MJ, Colditz GA, et al.: Postmenopausal hormone therapy and mortality. NEJM 1997;336:1769-1775.
50. Steele GD, Osteen RT, Winchester DP, et al.: National Cancer Database Annual Review of Patient Care, 1994. Chicago: American Cancer Society.
51. Hortobagyi GN, Buzdar AU, Marcus CE. et al.: Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. Natl Cancer Inst Monogr 1986;1:105-109.
52. Dnistrian AM, Schwartz MK, Fracchia AA, et al.: Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 1983;51:803-807.
53. Early Breast Cancer Trialists Collaborative Group: Ovarian ablation in early breast cancer: Overview of the randomized trials. Lancet 1996;348:1189-1196.
54. Davidson NE: Ovarian ablation as treatment for young women with breast cancer. Natl Cancer Inst Monogr 1994;16:95-99.
55. Lonning PE, Helle SI, Johannesson DC, et al.: Influence of plasma estrogen levels on length of disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 1996;39:335-341.
56. Stoll BA, Parbhoo S: Treatment of menopausal symptoms in breast cancer patients. Lancet 1988;1278-1279.
57. DiSaia PJ, Odicino F, Grosen EA, et al.: Hormone replacement therapy in breast cancer. Lancet 1993;342:1232.
58. Powles TJ, Hickish T, Casey S, et al.: Hormone replacement after breast cancer. Lancet 1993;342:60.
59. Wile AG, Opfell RW, Margileth DA: Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372-375.
60. Vassilopoulou-Sellin R, Theriault R, Klein MJ: Estrogen replacement therapy in women with a prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997;65:89-93.
61. Eden JA, Bush T, Nand S, et al.: A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995;2:67-72.
62. Dhodapkar MV, Ingle JN, Ahmann DL: Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995;75:43-46.
63. Vassilopoulou-Sellin R, Theriault RL: Randomized prospective trial of estrogen replacement therapy in women with a history of breast cancer. JNCI Monogr 1994;16:153-159.
64. Laya MB, Lawson EB, White E: Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. JNCI 1996;88:643-649.
65. Lane JM: Osteoporosis: Medical prevention and treatment. Spine 1997;22:32-37.
66. Hosking D, Chilvers CED, Christiansen C, et al.: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 1998:485-492.
67. Powles TJ, McCloskey E, Paterson AHG, et al.: Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. JNCI 1998;90:704-708.
68. Seeman E. Osteoporosis: Trials and tribulations. Am J Med 1997;103:74-89.
69. Kessel B: Alternatives to estrogen for menopausal women. Proc Soc Exp Biol Med 1998;217:38-44.
70. Clarkson TB, Anthony MS, Williams JK, et al.: The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy. Proc Soc Exp Biol Med 1998;217:365-368.
71. Love RR, Newcomb PA, Wiebe DA, et al.: Effects of Tamoxifen therapy on lipid and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70:1132-1135.
72. Love RR, Mazess RB, Barden HS, et al.: Effect of Tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl J Med 1992;326:852-856.
73. Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: Report of the National surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
74. Magriples U, Naftolin F, Schwartz PE, et al.: High-grade endometrial carcinoma in Tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-490.
75. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294.
76. Gorin MB, Day R, Costantino JP, et al.: Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthamol 1998; 125:493-501.
77. Lum SS, Woltering EA, Fletcher WS, et al.: Changes in serum estrogen levels in women during tamoxifen therapy. Am J Surg 1997;173:399-402.
78. Delmas PD, Bjarnason NH, Mitlak BH, et al.: Effects of Raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women, New Engl J Med 1997;337:1641-1647.
79. th Annual ASCO Meeting, Los Angeles, CA. 1998.
80. Ratajczak HV, Sothern RB, Hrushesky WJM. Estrous cycle influence on surgical cure of a mouse breast cancer. J Exp Med 1988;168:73-83.
81. Hrushesky WJM, Gruber SA, Sothem RB, et al.: Natural killer cell activity: Age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. J Natl Cancer Inst 1988;80:1232-1237.
82. Hrushesky WM, Bluming AZ, Gruber SA, et al.: Menstrual influence on surgical cure of breast cancer. Lancet 1989;2:949-952.
83. Veronesi U, Luini A, Mariani L, et al.: Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994;343:1544-1546.
84. Senie RT, Rosen PP, Rhodes P, et al.: Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med 1991;115:337-342.
85. Marques LA, Franco EL: Association between timing of surgery during menstrual cycle and prognosis in pre-menopausal breast cancer. Int J Cancer 1993;53:707-708.
86. Badwe RA, Gregory WM, Chaudary MA, et al.: Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1991;337:1261-1264.
87. Saad Z, Bramwell V, Duff J, et al.: Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer. Br J Surg 1994;81:217-220.
88. Spratt JS, Zirnheld J, Yancey JM: Breast cancer detection demonstration project data can determine whether the prognosis of breast cancer is affected by the timing of surgery during the menstrual cycle. J Surg Oncol 1993;53:4-9.
89. Badwe RA, Wang DY, Gregory WM, et al.: Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer 1994;30A:445-448.
90. Chang S, Hulka BS, Baird DD, et al.: Breast cancer survival and the timing of tumor removal during the menstrual cycle. Cancer Epidemiol Biomarkers Prev 1997;6:881-886.
91. Sainsbury R, Jones M, Parker D: Timing of surgery for breast cancer and menstrual cycle. Lancet 1991;338:391-392.
92. Powles TJ, Ashley SE, Nash AG, Tidy A, Gazet JC, Ford HT, Timing of surgery in breast cancer (letter). Lancet 1991;337: 1604.
93. Randal J. Does timing of breast cancer surgery affect survival? J Natl Cancer Inst 1997;89:473-477.
94. Saad Z, Bramwell VHC, Wilson SM, et al.: Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet 1998; 351:1170-1173.
95. Tannenbaum A, Silverstone H: Nutrition and relation to cancer. Advances in Cancer Res 1953;1:451-465.
96. Tannenbaum A. The genesis and growth of tumors: effects of a high-fat diet. Cancer Res 1942;2:468-475.
97. Fischer SM, Conti CJ, Locniskar M, et al.: The effect of dietary fat on the rapid development of mammary tumors induced by 7,12-Dimethylbenz(a)anthracene in SENCAR Mice. Cancer Res 1992;52:662-666.
98. Rose DP, Connolly JM, Liu XH: Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines in vitro. Cancer Res 1994;54:6557-6562.
99. Ip C, Carter CA, Ip MM: Requirement of essential fatty acid for mammary tumorigenesis in the rat. Cancer Res 1985;45:1997-2001.
100. Freedman LS, Clifford C, Messina M: Analysis of dietary fat, calories,body weight, and the development of mammary tumors in rats and mice; a review. Cancer Res 1990;50:5710-5719.
101. Ries LAG, Kosary CL, Hankey BF, Miller BA, et al.: SEER Cancer statistics review, 1973-1994: Tables and Graphs. Bethesda, MD: National Cancer Institute; 1997. NIH Publication no. 97-2789.
102. Wynder EL, Cohen LA, Muscat JE, Winters B, Dwyer JT, Blackburn G: Breast cancer: Weighing the evidence for a promoting role of dietary fat. JNCI 1997;89:766-775.
103. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, et al.: Migration patterns and breast cancer risk in Asian-American women. JNCI 1993;85:1819-1827.
104. Prentice RL, Sheppard L: Dietary fat and cancer: Consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control 1990;1:81-97.
105. Hopkins GJ, Kennedy TG, Carroll KK: Polyunsaturated fatty acids as promoters of mammary carcinogenesis induced in Sprague-Dawley rats by 7,12-Dimethylbenz(a)nthracene. JNCI 1981;66:517-522.
106. Lasekan JB, Clayton MK, Gendron-Fitzpatrick A, Ney DM: Dietary olive and safflower oils in promotion of DMBA-induced mammary tumorigenesis in rats. Nutrition Cancer 1990;13:153-163.
107. Howe GR, Hirohata T, Hislop G, Iscovich JM, Yuan JM, Katsouyanni K, Lubin F, Marubini E, Modan B, Rohan T, Toniolo P, Shunzhang Y: Dietary factors and risk of breast cancer: Combined analysis of 12 case-control studies. JNCI 1990;82:561-569.
108. Kannel W, Gordon T: The Framingham study. An epidemiologic investigation of cardiovascular diseases. Section 24: The Framingham diet study: Diet and the regulation of serum cholesterol. Washington, D.C. US Government Printing Office, 1970.
109. Nichols AB, Ravenscroft C, Lamphier DE, Ostrander LD: Daily nutritional intake and serum lipid levels. The Tecumseh study. Am J Clin Nutr 1976;29:1384-1392.
110. Hunter DJ, Spiegelman D, Adami H-O, Beeson L, VanDenBrandt PA, Folsom AR, Fraser GE, Goldbohm A, Graham S, Howe G, Kushi LH, Marshall JR, McDermott A, Miller AB, Speizer FE, Wolk A, Shiaw-Shyuan Y, Willett W: Cohort studies of fat intake and the risk of breast cancer: A pooled analysis. NEJM 1996; 334:356-361.
111. Verreault R, Brisson J, Deschenes L, Naud F, Meyer F, Belanger L: Dietary fat in relation to prognostic indicators in breast cancer. JNCI 1988;80:819-825.
112. Holm L-E, Nordevang E, Hjalmar M-L, Lidbrink E, Callmere E, Nilsson B: Treatment failure and dietary habits in women with breast cancer. JNCI 1993;85:32-36.
113. Gregorio DI, Emrich LJ, Graham S, Marshall JR, Nemoto T: Dietary fat consumption and survival among women with breast cancer. JNCI 1985;75:37-41.
114. Chlebowski RT, Blackburn GL, Buzzard M, Rose DP, Martino S, Khandekar JD, York M, Jeffery RW, Elashoff RM, Wynder EL: Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. J Clin Oncol 1993;11:2072-2080.
115. Coates RJ, Clark WS, Eley JW, Greenberg RS, Huguley CM, Brown RL: Race, nutritional status, and survival from breast cancer. JNCI 1990;82:1684-1692.
116. Jones BA, Kasi SV, Curnen MG, Owens PH, Dubrow R: Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol 1997;146: 394-404.
117. Woods MN, Barnett JB, Spiegelman D, Trail N, Hertzmark E, Longcope C, Gorbach SL: Hormone levels during dietary changes in premenopausal African-American women. JNCI 1996;88:1369-1374.
118. Jones LA, Gonzales R, Gomez S, Ritenbaugh C, Pillow PI, Chilton J, Arostegui S, Hajek RA: Dietary intervention model for cancer prevention studies in African American women. Proceedings of the American Association for Cancer Research 1997; Vol 38: Abstract #743.
119. Boyd NF, Greenberg C, Lockwood G, Little L, Martin L, Byng J, Yaffe M, Tritchler D: Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: Results from a randomized trial. JNCI 1997;89:488-496.
120. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R: Mammographic features and breast cancer risk: Effects with lime, age, and menoipause status. JNCI 195;87: 1622-1629
121. Stoll BA: Diet and exercise regimens to improve breast carcinoma prognosis. Cancer 1996;78:2465-2470.
122. Campbell MJ, Koeffler HP: Toward therapeutic intervention of cancer by vitamin D compounds. JNCI 1997;89:182-183.
123. 5. J Natl Cancer Inst 1997;89:212-218.
124. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991;129:832-837.
125. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci 1993;90: 2690-2694.
126. Messina MJ, Persky V, Setchell KDR, Barnes S: Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutrition Cancer 1994;21:113-131.